Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC), R Paridaens, L Dirix, C Lohrisch, L Beex, M Nooij, D Cameron, L Biganzoli, T Cufer, L Duchateau, A Hamilton, J P Lobelle, M Piccart

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science